PROPANC BIOPHARMA, INC.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | 66.0% | 82.9% | -15,464.1% |
| FY2022 | 87.9% | 126.7% | -3,255.4% |
| FY2023 | 85.4% | 97.6% | -4,410.2% |
| FY2024 | 48.2% | 53.9% | -2,515.8% |
| FY2025 | -423.7% | -407.9% | -300.1% |
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2021 | 66.0% | 82.9% | -15,464.1% |
| FY2022 | 87.9% | 126.7% | -3,255.4% |
| FY2023 | 85.4% | 97.6% | -4,410.2% |
| FY2024 | 48.2% | 53.9% | -2,515.8% |
| FY2025 | -423.7% | -407.9% | -300.1% |